Ipsen (OTC:IPSEY) Stock, Quote.Headers.trade-ideas

IPSEN S.A. ADR

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

News

Health Care

Media

General

GNFT

IPSEF

IPSEY

The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug&#39;s ability to reduce alkaline phosphatase levels, marks a significant advancement in therapies available for PBC.

FDA Fast-Tracks Ipsen And Genfit&#39;s New Liver Disease Treatment, Iqirvo

Biotech

Trading Ideas

EXEL

RHHBF

RHHBY

RHHVF

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&amp;nbs

Third Time Lucky: Exelixis&#39; Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients

Analyst Color

Penny Stocks

Small Cap

Analyst Ratings

Movers

CBAY

Friday, CymaBay Therapeutics Inc&#39;s (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC: 

Genfit&#39;s Miss Is CymaBay Therapeutics&#39; Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class

Ipsen SA

Press Releases

Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins

Ipsen announces issuance of €500 million inaugural Rated Public Bond

Earnings

Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication

Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis

Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma

PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

Ipsen - Half year statement - 2025 06 30

GEHC

LNTH

PARIS:IPN

Ipsen

Comments

Ipsen

Ipsen (OTC:IPSEY) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell